-
Valeant's SILIQ Will Be Priced At $3,500 A Month
Friday, April 21, 2017 - 8:53am | 315Read More...Troubled pharmaceutical company Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on Friday pricing for its SILIQ (brodalumab) injection. What Is SILIQ? The U.S. Food and Drug Administration approved the Biologics License Application for SILIQ, which is a monoclonal antibody that targets the...
-
Morgan Stanley Cuts Valeant's Target To $25, Admits It Got A Couple Things Wrong
Thursday, November 10, 2016 - 10:06am | 388Read More...Morgan Stanley has slashed its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares by $17 to $25, saying it underestimated generic pressures on the company's older franchises and the risk of an ex-U.S. franchise slowdown. The latest action follows Valeant’s poor third-...
-
Why Shares Of Valeant Pharmaceuticals Spiked
Monday, January 25, 2016 - 2:17pm | 205Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading higher by more than 6 percent on Monday after the company announced the Food and Drug Administration has accepted for review the Biologics License Application (BLA) the company submitted as part of a partnership with AstraZeneca...
-
Amgen, AstraZeneca End Development Pact; Shares Sink
Tuesday, May 26, 2015 - 8:56pm | 331Read More...Amgen, Inc. (NASDAQ: AMGN) shares lost about 2.8 percent Tuesday on fallout from the termination of a three-year-old development pact with AstraZeneca plc (NYSE: AZN). Amgen closed at $159.02, off $4.57; AstraZeneca declined 2.5 percent to $67.68. Amgen said late Friday that it would end a co...
